AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

AstraZeneca said its China president Leon Wang is under investigation and the drugmaker would cooperate with Chinese ...

She added: “This greenfield investment will add significant capabilities to Singapore’s growing biopharmaceutical sector, especially in the development and manufacturing of precision medicines for ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Drugs for patients with respiratory diseases like asthma ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

New Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class.